What is Curve Biosciences?
Based in San Mateo, California, Curve Biosciences operates as a pioneer in the Whole-Body Intelligence space. The company has developed a sophisticated molecular blueprint of the human body, utilizing the world's largest collection of comprehensively-characterized tissue samples. By training its intelligence models on this atlas, Curve provides clinicians with the ability to identify chronic disease states through its Whole-Body Blood Tests with unprecedented accuracy and speed.
The company's market position is defined by its transition from traditional diagnostic methods to a proactive, data-centric approach. By identifying health anomalies earlier than conventional screening, Curve Biosciences aims to alleviate the systemic burden of chronic disease, providing doctors with actionable intelligence that improves patient outcomes and shifts the paradigm of modern medicine toward preventative care.
How much funding has Curve Biosciences raised?
Curve Biosciences has raised a total of $40M across 1 funding round:
Other Financing Round
$40M
Other Financing Round (2025): $40M with participation from First Spark Ventures, Civilization Ventures, Luma Group, Techas Capital, and LifeX Ventures
Key Investors in Curve Biosciences
First Spark Ventures
First Spark Ventures is a Deep Tech venture capital fund that invests in breakthrough technologies aimed at enhancing health, safety, and productivity, with a focus on digital biology and biotech.
Civilization Ventures
Civilization Ventures is a venture capital firm that invests in innovative companies within the health tech and biopharma sectors, focusing on preventative, personalized, and regenerative healthcare solutions.
Luma Group
Luma Group is an investment firm focused on the greatest breakthrough scientific discoveries that leverage advanced computation and AI.
What's next for Curve Biosciences?
With this major enterprise-level funding, Curve Biosciences is poised to accelerate the commercialization of its diagnostic platform. The strategic roadmap likely includes expanding the depth of its Whole-Body Atlas and enhancing the predictive capabilities of its AI-driven models. As the company scales, it will focus on integrating its diagnostic solutions into broader clinical workflows, thereby solidifying its role as a critical infrastructure provider in the future of personalized medicine. The backing from specialized venture firms suggests a long-term commitment to scaling deep-tech solutions that bridge the gap between advanced computation and biological discovery.
See full Curve Biosciences company page
